A new affordable generic
version of a frontline antiretroviral drug was launched in Kenya on 28 June
2017, the first time that HIV patients will have access to the more affordable
version of the treatment.
Dolutegravir (DTG)
will be available to patients through a partnership between the Kenyan Ministry
of Health and the Geneva-based company Unitaid.
DTG has been the
preferred first-line treatment in the United States and Canada since 2014, a
year after it came onto the market. Prior to the current introduction, Kenyan
patients paid $50-$60 for a 30-day supply pack. This generic version costs
about $4 a pack.
The generic DTG
launch is part of a $34-million three-year Optimal ARV project by Unitaid and
the Clinton Health Access Initiative aimed at accelerating access to affordable
antiretroviral treatments across 11 countries.
Globally, there are
more than 36 million people living with HIV, of which roughly half are
untreated. The World Health Organization (WHO) estimates that by expanding the
use of antiretroviral therapy, almost 600,000 deaths can be prevented each year
by 2020.
Scaling up HIV
treatment in low- and middle-income countries has been a major health success
over the past 15 years. However, ensuring that more people living with HIV have
access to medicine is crucial to ending the AIDS epidemic by 2030.
DTG was approved for
use in 2013 in the United States and Canada, and was adopted the following year
by the European Commission as a first-line drug. Since 2015, WHO has also
recommended DTG as the alternative first-line treatment. Last year,
Botswana became the first African country to purchase DTG.
DTG has been
recognized as the optimal treatment in recent years because of its superior
efficacy: providing better treatment outcomes to patients taking them, fewer
side effects, and higher barrier resistance, meaning the HIV virus is less able
to develop resistance. If resistance to HIV medicine builds, a patient must be
switched to second- or third-line treatments that can cost up to 10 times more.
The generic DTG will
be offered through a “catalytic procurement” process that will initially work
with public health facilities, prioritizing patients intolerant of the current
first-line treatment, Efavirenz.
Over the next six
months, Kenyan health officials will have an opportunity to address large-scale
rollout plans, discuss how health care providers can access the medicine, and
prepare distribution channels before prescribing significantly higher volumes
next year.
Twenty-seven thousand
people in Kenya are expected to benefit from the DTG treatments.
Devex, 28 June 2017
MARTINA NICOLLS is an international
aid and development consultant, and the author of:- Similar But Different
in the Animal Kingdom (2017), The Shortness of Life: A Mongolian Lament
(2015), Liberia’s Deadest Ends (2012), Bardot’s Comet (2011), Kashmir on a
Knife-Edge (2010) and The Sudan Curse (2009).
Comments
Post a Comment